Pharma Sales

Price growth drove India's pharmaceutical sales in 2022, shows data

Data shows that in calendar year 2022, price driven growth rate has been 6 per cent; growth from new products has been 1.7 percent, while volume growth has been zero

Bitter medicine for pharma regulation

The Gambian tragedy has raised uncomfortable questions about drug regulation in India. The Truth Pill is a depressing but eye-opening reality check of the regulatory landscape

Pharma logs 17% growth in Nov; anti-infective therapy drives market demand

Key antibiotic brands like Augmentin (GSK) and Clavam (Alkem) clocked 25 per cent and 29 percent growth, respectively, in November, the data showed

We won't make an acquisition just because we have to: Piramal Pharma chief

In a Q&A, Nandini Piramal, chairperson of the firm, says the company currently sees great scope in expanding and organically growing the OTC business, and wants to build more consumer focused brands

Udaan starts multiple deliveries per day for pharmacies in six cities

Softbank-backed B2B e-commerce firm Udaan has started delivering stocks to pharmacies four times a day across six cities and plans to scale up the service to other places after six to eight months, the company said on Thursday. The 4X4 delivery service' has been rolled out after a pilot programme and receiving extensive feedback from pharmacies in select cities, which required enhanced delivery capabilities. During the pilot phase, the business witnessed a 45 per cent rise in orders in the select cities. "As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities - Kolkata, Jaipur, Indore, Ahmedabad, Bengaluru and Pune. Udaan plans to scale the '4X4 delivery service' to more cities and towns in the next 6-8 months," the company said in a statement. Udaan Business head for Pharma Category Sanjay Sharma said the company will leverage for the convenience and faster ...

Pharma supply start-up Saveo Healthcare raises $4.5mn in venture round

Company founded by 4 IIT graduates will use money to expand its presence and for improving technology

Land parcels of pharma PSUs find no takers, but momentum likely in few mths

In December 2019 the decision was revised to allow sale of land to private entities as well through a competitive bidding process

NLEM 2022: Analysts see no major impact pharma companies' growth

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

Demand tonic to spur pharma growth in FY22: A CRISIL analysis

But exports to stay under the weather; credit outlook remains stable

Indian pharma companies' sales to rise after resilience in FY21: Fitch

Indian pharmaceutical companies' sales will grow robustly in the financial year ending March 2022 (FY22) as sales normalise in categories affected by the pandemic in previous year, Fitch Ratings said

FabiFlu numero uno in Indian pharma market, show April sales data

With sales of Rs 352 crore in April, this brand alone accounted for over 2 per cent of the total domestic pharma market sales of Rs 15,662 crore

India's pharma market rebounds in April, clocks 51.5% sales growth

Low base of April 2020, pick-up in demand for Covid-19 drugs major contributors to growth

Investors turn to pharma stocks amid market crash; Nifty Pharma gains 1.5%

Among individual stocks, Lupin zoomed 3.4 per cent in the intra-day trade and hit a high of Rs 1,060, Sun Pharmaceuticals advanced 2 per cent, and Dr Reddy's Labs gained 1.7 per cent.

Weak Q3 show, margin pressures to keep Sanofi stock under pressure

Growth led by power brands and new launches could recover as pandemic impact wanes

Weak US outlook in near term, higher costs to weigh on Torrent Pharma

While the stock has corrected, valuations leave little room for upside

Torrent Pharma Q3 net up by 18% to Rs 297 cr even as US revenues dip

India revenues grew 7% to stand at Rs 930 cr. Company's consolidated total revenue from operations fell marginally by under 1% to Rs 2,003 cr in Q3FY21

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Divestment of US subsidiary to leave Aurobindo Pharma cash positive

Divestment of the US subsidiary is at good valuations and will help attain net cash positive status

Despite volume lag, drug firms hike price as domestic sales rebound

Motilal Oswal analysts also said that while price growth for non-NLEM products stood at 4.8 per cent YoY, NLEM products saw a price rise of 3.6 per cent

GSK Pharma's growth challenges to remain in near term as Covid dents sales

Even as overall pharma market was up 5% over the year-ago period, GSK's September sales were down 8%, the firm is banking on recovery led by top brands, new launches